Different DNA damage and cell cycle checkpoint control in low- and high-risk human papillomavirus infections of the vulva

International Journal of Cancer

Volumn 130, Issue 12, 2012, Pages 2874-2885

  Santegoets, Lindy A M ^a   Baars, Romy Van ^a   Terlou, Annelinde ^a   Heijmans Antonissen, Claudia ^a   Swagemakers, Sigrid M A ^a,b   Van Der Spek, Peter J ^a   Ewing, Patricia C ^a   Beurden, Marc Van ^c   Van Der Meijden, Willem I ^d   Helmerhorst, Theo J M ^a   Blok, Leen J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Cancer Genomics Centre   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d Havenziekenhuis   (Netherlands)

Author keywords

condylomata; high risk; HPV; low risk; uVIN

Indexed keywords

BRCA1 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; ESTROGEN RECEPTOR; FANCONI ANEMIA GROUP A PROTEIN; FANCONI ANEMIA GROUP D2 PROTEIN; GAMMA HISTONE H2AX; HISTONE H2AX; PROTEIN P53; RAD51 PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CELL CYCLE CHECKPOINT; CELL CYCLE REGULATION; CLINICAL ARTICLE; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; DNA DAMAGE; FEMALE; GENE EXPRESSION PROFILING; HEAD AND NECK CANCER; HIGH RISK HUMAN PAPILLOMAVIRUS INFECTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOW RISK HUMAN PAPILLOMAVIRUS INFECTION; MICROARRAY ANALYSIS; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; UTERINE CERVIX CANCER; VIRUS CARCINOGENESIS; VULVA CANCER; VULVA DISEASE; VULVA INTRAEPITHELIAL NEOPLASIA; VULVA TUMOR;

ALPHAPAPILLOMAVIRUS; BRCA1 PROTEIN; CELL CYCLE CHECKPOINTS; CONDYLOMATA ACUMINATA; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA DAMAGE; DNA REPAIR; DNA, VIRAL; FANCONI ANEMIA COMPLEMENTATION GROUP A PROTEIN; FANCONI ANEMIA COMPLEMENTATION GROUP D2 PROTEIN; FEMALE; GENE EXPRESSION PROFILING; HISTONES; HUMANS; PAPILLOMAVIRUS INFECTIONS; RAD51 RECOMBINASE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; VULVA; VULVAR DISEASES;

EID: 84859913579     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26345     Document Type: Article

References (46)

1. Syrjanen KJ,. Epidemiology of human papillomavirus (HPV) infections and their associations with genital squamous cell cancer. Review article. APMIS 1989; 97: 957-70. (Pubitemid 19285632)
2. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD,. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338: 423-8. (Pubitemid 28135669)
3. Sankaranarayanan R, Ferlay J,. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res 2006; 20: 207-25. (Pubitemid 43380597)
4. D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, Westra WH, Gillison ML,. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356: 1944-56. (Pubitemid 46740304)
5. Kreimer AR, Clifford GM, Boyle P, Franceschi S,. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005; 14: 467-75. (Pubitemid 40270113)
6. Pim D, Banks L,. Interaction of viral oncoproteins with cellular target molecules: infection with high-risk vs. low-risk human papillomaviruses. APMIS 2010; 118: 471-93.
7. Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, Barr E, Haupt RM, Joura EA,. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009; 199: 805-14.
8. Dinh TH, Sternberg M, Dunne EF, Markowitz LE,. Genital warts among 18- to 59-year-olds in the United States, national health and nutrition examination survey, 1999-2004. Sex Transm Dis 2008; 35: 357-60. (Pubitemid 351440776)
9. Santegoets LA, van Seters M, Heijmans-Antonissen C, Kleinjan A, van Beurden M, Ewing PC, Kuhne LC, Beckmann I, Burger CW, Helmerhorst TJ, Blok LJ,. Reduced local immunity in HPV-related VIN: expression of chemokines and involvement of immunocompetent cells. Int J Cancer 2008; 123: 161-22.
10. Pett M, Coleman N,. Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? J Pathol 2007; 212: 356-67. (Pubitemid 47099012)
11. Hopman AH, Smedts F, Dignef W, Ummelen M, Sonke G, Mravunac M, Vooijs GP, Speel EJ, Ramaekers FC,. Transition of high-grade cervical intraepithelial neoplasia to micro-invasive carcinoma is characterized by integration of HPV 16/18 and numerical chromosome abnormalities. J Pathol 2004; 202: 23-33. (Pubitemid 38072842)
12. Andersson S, Safari H, Mints M, Lewensohn-Fuchs I, Gyllensten U, Johansson B,. Type distribution, viral load and integration status of high-risk human papillomaviruses in pre-stages of cervical cancer (CIN). Br J Cancer 2005; 92: 2195-200. (Pubitemid 40966257)
13. Klaes R, Woerner SM, Ridder R, Wentzensen N, Duerst M, Schneider A, Lotz B, Melsheimer P, von Knebel DM,. Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. Cancer Res 1999; 59: 6132-6. (Pubitemid 30035633)
14. Hillemanns P, Wang X,. Integration of HPV-16 and HPV-18 DNA in vulvar intraepithelial neoplasia. Gynecol Oncol 2006; 100: 276-82. (Pubitemid 43078480)
15. van de Nieuwenhof HP, van Kempen LC, de Hullu JA, Bekkers RL, Bulten J, Melchers WJ, Massuger LF,. The etiologic role of HPV in vulvar squamous cell carcinoma fine tuned. Cancer Epidemiol Biomarkers Prev 2009; 18: 2061-7.
16. van Seters M, van Beurden M, de Craen AJ,. Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients. Gynecol Oncol 2005; 97: 645-51. (Pubitemid 40614916)
17. van Seters M, van Beurden M, ten Kate FJ, Beckmann I, Ewing PC, Eijkemans MJ, Kagie MJ, Meijer CJ, Aaronson NK, Kleinjan A, Heijmans-Antonissen C, Zijlstra FJ, et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med 2008; 358: 1465-73. (Pubitemid 351482738)
18. Santegoets LA, Seters M, Helmerhorst TJ, Heijmans-Antonissen C, Hanifi-Moghaddam P, Ewing PC, van Ijcken WF, van der Spek PJ, van der Meijden WI, Blok LJ,. HPV related VIN: highly proliferative and diminished responsiveness to extracellular signals. Int J Cancer 2007; 121: 759-66. (Pubitemid 47106204)
19. Livak KJ, Schmittgen TD,. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ÎÎC(T)) Method. Methods 2001; 25: 402-8. (Pubitemid 34164012)
20. Zhai Y, Bommer GT, Feng Y, Wiese AB, Fearon ER, Cho KR,. Loss of estrogen receptor 1 enhances cervical cancer invasion. Am J Pathol 2010; 177: 884-95.
21. Talbi S, Hamilton AE, Vo KC, Tulac S, Overgaard MT, Dosiou C, Le Shay N, Nezhat CN, Kempson R, Lessey BA, Nayak NR, Giudice LC,. Molecular phenotyping of human endometrium distinguishes menstrual cycle phases and underlying biological processes in normo-ovulatory women. Endocrinology 2006; 147: 1097-121. (Pubitemid 43244341)
22. Hanifi-Moghaddam P, Boers-Sijmons B, Klaassens AH, van Wijk FH, den Bakker MA, Ott MC, Shipley GL, Verheul HA, Kloosterboer HJ, Burger CW, Blok LJ,. Molecular analysis of human endometrium: short-term tibolone signaling differs significantly from estrogen and estrogen + progestagen signaling. J Mol Med 2007; 85: 471-80. (Pubitemid 46701656)
23. Slebos RJ, Yi Y, Ely K, Carter J, Evjen A, Zhang X, Shyr Y, Murphy BM, Cmelak AJ, Burkey BB, Netterville JL, Levy S, et al. Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res 2006; 12: 701-9. (Pubitemid 43259848)
24. Pyeon D, Newton MA, Lambert PF, den Boon JA, Sengupta S, Marsit CJ, Woodworth CD, Connor JP, Haugen TH, Smith EM, Kelsey KT, Turek LP, et al. Fundamental differences in cell cycle deregulation in human papillomavirus- positive and human papillomavirus-negative head/neck and cervical cancers. Cancer Res 2007; 67: 4605-19. (Pubitemid 46910165)
25. Spardy N, Duensing A, Hoskins EE, Wells SI, Duensing S,. HPV-16 E7 reveals a link between DNA replication stress, fanconi anemia D2 protein, and alternative lengthening of telomere-associated promyelocytic leukemia bodies. Cancer Res 2008; 68: 9954-63.
26. Carvalho JP, Dias ML, Carvalho FM, Del Pilar Estevez Diz M, Petito JW,. Squamous cell vulvar carcinoma associated with Fanconi's anemia: a case report. Int J Gynecol Cancer 2002; 12: 220-2. (Pubitemid 34477887)
27. Han TJ, Lee CH, Yoo CW, Shin HJ, Park HJ, Cho KH, Park JY, Choi SW, Kim JY,. Synchronous multifocal HPV-related neoplasm involving both the genital tract and the head-and-neck area: a case report of Fanconi anemia. Radiother Oncol 2009; 92: 138-41.
28. Wilkinson EJ, Morgan LS, Friedrich EG, Jr,. Association of Fanconi's anemia and squamous-cell carcinoma of the lower female genital tract with condyloma acuminatum. A report of two cases. J Reprod Med 1984; 29: 447-53. (Pubitemid 14053854)
29. Mousavi A, Abbasi F, Abadi AG, Hashemi FA,. Vulvar squamous cell carcinoma associated with Fanconi's anemia. Int J Hematol 2010; 91: 498-500.
30. Wang W,. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev 2007; 8: 735-48. (Pubitemid 47429206)
31. Zhu W, Dutta A,. Activation of fanconi anemia pathway in cells with re-replicated DNA. Cell Cycle 2006; 5: 2306-9. (Pubitemid 44785837)
32. Spardy N, Duensing A, Charles D, Haines N, Nakahara T, Lambert PF, Duensing S,. The human papillomavirus type 16 E7 oncoprotein activates the Fanconi anemia (FA) pathway and causes accelerated chromosomal instability in FA cells. J Virol 2007; 81: 13265-70. (Pubitemid 350156966)
33. Hoskins EE, Morris TA, Higginbotham JM, Spardy N, Cha E, Kelly P, Williams DA, Wikenheiser-Brokamp KA, Duensing S, Wells SI,. Fanconi anemia deficiency stimulates HPV-associated hyperplastic growth in organotypic epithelial raft culture. Oncogene 2009; 28: 674-85.
34. Junttila MR, Evan GI,. p53-a Jack of all trades but master of none. Nat Rev Cancer 2009; 9: 821-9.
35. Moody CA, Laimins LA,. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 2010; 10: 550-60.
36. Hoevenaars BM, van der Avoort IA, de Wilde PC, Massuger LF, Melchers WJ, de Hullu JA, Bulten J,. A panel of p16(INK4A). MIB1 and p53 proteins can distinguish between the 2 pathways leading to vulvar squamous cell carcinoma. Int J Cancer 2008; 123: 2767-73.
37. van der Avoort IA, van de Nieuwenhof HP, Otte-Holler I, Nirmala E, Bulten J, Massuger LF, van der Laak JA, Slootweg PJ, de Hullu JA, van Kempen LC,. High levels of p53 expression correlate with DNA aneuploidy in (pre)malignancies of the vulva. Hum Pathol 2010; 41: 1475-85.
38. Yoshida K, Miki Y,. The cell death machinery governed by the p53 tumor suppressor in response to DNA damage. Cancer Sci 2010; 101: 831-5.
39. Rahkola P, Mikkola TS, Ylikorkala O, Vaisanen-Tommiska M,. Association between high risk papillomavirus DNA and nitric oxide release in the human uterine cervix. Gynecol Oncol 2009; 114: 323-6.
40. Wei L, Gravitt PE, Song H, Maldonado AM, Ozbun MA,. Nitric oxide induces early viral transcription coincident with increased DNA damage and mutation rates in human papillomavirus-infected cells. Cancer Res 2009; 69: 4878-84.
41. Kreuter A, Wieland U, Gambichler T, Altmeyer P, Pfister H, Tenner-Racz K, Racz P, Potthoff A, Brockmeyer NH,. p16ink4a expression decreases during imiquimod treatment of anal intraepithelial neoplasia in human immunodeficiency virus-infected men and correlates with the decline of lesional high-risk human papillomavirus DNA load. Br J Dermatol 2007; 157: 523-30. (Pubitemid 47256116)
42. Davidson EJ, Morris LS, Scott IS, Rushbrook SM, Bird K, Laskey RA, Wilson GE, Kitchener HC, Coleman N, Stern PL,. Minichromosome maintenance (Mcm) proteins, cyclin B1 and D1, phosphohistone H3 and in situ DNA replication for functional analysis of vulval intraepithelial neoplasia. Br J Cancer 2003; 88: 257-62. (Pubitemid 36255845)
43. Malinowski DP,. Molecular diagnostic assays for cervical neoplasia: emerging markers for the detection of high-grade cervical disease. Biotechniques 2005;(Suppl): 17-23.
44. Branca M, Ciotti M, Giorgi C, Santini D, Di Bonito L, Costa S, Benedetto A, Bonifacio D, Di Bonito P, Paba P, Accardi L, Syrjanen S, et al. Up-regulation of proliferating cell nuclear antigen (PCNA) is closely associated with high-risk human papillomavirus (HPV) and progression of cervical intraepithelial neoplasia (CIN), but does not predict disease outcome in cervical cancer. Eur J Obstet Gynecol Reprod Biol 2007; 130: 223-31. (Pubitemid 46097249)
45. Spardy N, Covella K, Cha E, Hoskins EE, Wells SI, Duensing A, Duensing S,. Human papillomavirus 16 E7 oncoprotein attenuates DNA damage checkpoint control by increasing the proteolytic turnover of claspin. Cancer Res 2009; 69: 7022-9.
46. Lakshmi S, Rema P, Somanathan T,. p16ink4a is a surrogate marker for high-risk and malignant cervical lesions in the presence of human papillomavirus. Pathobiology 2009; 76: 141-8.